Skip to main content

Table 4 Factors associated with 12-month virological success (<500 copies/mL) in the 106 HIV-1-infected children randomised in the ANRS 12206 MONOD study (Abidjan and Ouagadougou, February 2013–February 2015): logistic regression

From: Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d’Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial

  Univariate Adjusted modela
  OR CI (95%) p value aOR CI (95%) p value
Abidjan vs. Ouagadougou 1.13 (0.38–3.35) 0.83 0.64 (0.17–2.41) 0.51
Female vs. Male 1.14 (0.40–3.23) 0.81 1.26 (0.41–3.93) 0.68
Treatment arm    0.73    0.66
 AZT/ABC + 3TC + LPV/r Ref.   Ref.  
 ABC + 3TC + EFV 0.83 (0.29–2.35)   0.78 (0.26–2.38)  
Mother main caregiver vs. father or other 1.06 (0.27–4.14) 0.94  
Father informed of HIV status of the child 1.74 (0.61–4.93) 0.30  
History of antiretroviral drug exposure    0.68    0.34
 No previous exposure to any PMTCT or ART Ref.   Ref.  
 Prenatal maternal ART 0.58 (0.10–3.51)   0.32 (0.04–2.32)  
 Exposure to PMTCT only 0.90 (0.25–3.26)   0.64 (0.15–2.68)  
 Exposure to postnatal maternal ART only 2.00 (0.22–18.33)   1.95 (0.20–19.24)  
 PMTCT and postnatal maternal ART 0.39 (0.08–1.94)   0.19 (0.03–1.21)  
Age at randomisation <24 months 1.63 (0.53–5.03) 0.39  
WHO clinical stage at randomisation    0.04    0.01
 Stage 1, 2, 3 Ref.   Ref.  
 Stage 4 0.31 (0.10–0.95)   0.18 (0.05–0.72)  
  1. OR Odds ratio, CI Confidence interval, aOR Adjusted odds ratio, AZT Zidovudine, 3TC Lamivudine, LPV/r Lopinavir-boosted ritonavir, ABC Abacavir, EFV Efavirenz, PMTCT Prevention of mother-to-child-transmission, ART Antiretroviral therapy, WHO World Health Organization
  2. aForced variables: country, sex, treatment arm and history of antiretroviral drug exposure